These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22534465)

  • 1. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT scans for diagnosing ovarian cancer recurrence.
    Kitajima K; Ueno Y; Suzuki K; Kita M; Ebina Y; Yamada H; Senda M; Maeda T; Sugimura K
    Eur J Radiol; 2012 Nov; 81(11):3557-62. PubMed ID: 22534465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.
    Kitajima K; Suzuki K; Nakamoto Y; Onishi Y; Sakamoto S; Senda M; Kita M; Sugimura K
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1490-8. PubMed ID: 20386901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan.
    Chiewvit S; Jiranantanakorn T; Apisarnthanarak P; Kanchaanapiboon P; Hannanthawiwat C; Ubolnuch K; Phongsawat N; Chiewvit P
    J Med Assoc Thai; 2013 Jun; 96(6):703-8. PubMed ID: 23951828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
    Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
    Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
    Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
    Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indeterminate pulmonary nodules on CT images in breast cancer patient: the additional value of 18F-FDG PET/CT.
    Evangelista L; Panunzio A; Cervino AR; Vinante L; Al-Nahhas A; Rubello D; Muzzio PC; Polverosi R
    J Med Imaging Radiat Oncol; 2012 Aug; 56(4):417-24. PubMed ID: 22883649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
    J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
    Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
    Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer.
    Nakamoto Y; Sakamoto S; Okada T; Senda M; Higashi T; Saga T; Togashi K
    AJR Am J Roentgenol; 2007 Jan; 188(1):257-67. PubMed ID: 17179375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
    Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
    Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications.
    Evangelista L; Baretta Z; Vinante L; Bezzon E; De Carolis V; Cervino AR; Gregianin M; Ghiotto C; Saladini G; Pomerri F; Muzzio PC
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):375-84. PubMed ID: 23013667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
    D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
    Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer.
    Zundel MT; Michel MA; Schultz CJ; Maheshwari M; Wong SJ; Campbell BH; Massey BL; Blumin J; Wilson JF; Wang D
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e825-32. PubMed ID: 21300450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
    Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
    Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To Enhance or Not to Enhance? The Role of Contrast Medium
    Massollo M; Fiz F; Bottoni G; Ugolini M; Paparo F; Puppo C; Provinciali N; Iacozzi M; Altrinetti V; Cistaro A; Cabria M; DeCensi A; Treglia G; Piccardo A
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34206116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.